Rimegepant, a CGRP Antagonist, in the Treatment of Visceral Sensation and Chronic Abdominal Pain: A Pilot Study
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Rimegepant (Primary)
- Indications Irritable bowel syndrome; Migraine
- Focus Therapeutic Use
Most Recent Events
- 05 Jun 2025 Status changed from active, no longer recruiting to completed.
- 11 May 2025 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2024 Planned primary completion date changed from 1 Mar 2025 to 1 May 2025.